ALLOGENE THERAPEUTICS INC's ticker is ALLO and the CUSIP is 019770106. A total of 154 filers reported holding ALLOGENE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 7.07 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $5,772,103 | +1.3% | 1,798,163 | 0.0% | 6.87% | -22.1% |
| Q3 2023 | $5,700,177 | -36.2% | 1,798,163 | 0.0% | 8.82% | -24.4% |
| Q2 2023 | $8,936,870 | +0.6% | 1,798,163 | 0.0% | 11.67% | -4.0% |
| Q1 2023 | $8,882,925 | -21.5% | 1,798,163 | 0.0% | 12.15% | -20.0% |
| Q4 2022 | $11,310,445 | -41.8% | 1,798,163 | 0.0% | 15.20% | -12.8% |
| Q3 2022 | $19,420,000 | -5.3% | 1,798,163 | 0.0% | 17.43% | +0.6% |
| Q2 2022 | $20,499,000 | +25.1% | 1,798,163 | 0.0% | 17.32% | +81.8% |
| Q1 2022 | $16,381,000 | -38.9% | 1,798,163 | 0.0% | 9.53% | -5.1% |
| Q4 2021 | $26,829,000 | -41.9% | 1,798,163 | 0.0% | 10.04% | -24.2% |
| Q3 2021 | $46,213,000 | -1.5% | 1,798,163 | 0.0% | 13.24% | +12.6% |
| Q2 2021 | $46,896,000 | -26.1% | 1,798,163 | 0.0% | 11.76% | -26.7% |
| Q1 2021 | $63,475,000 | +39.9% | 1,798,163 | 0.0% | 16.04% | +72.1% |
| Q4 2020 | $45,386,000 | -33.1% | 1,798,163 | 0.0% | 9.32% | -78.1% |
| Q3 2020 | $67,809,000 | – | 1,798,163 | – | 42.47% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vida Ventures Advisors, LLC | 1,798,163 | $26,829,000 | 10.04% |
| Wildcat Capital Management, LLC | 1,716,370 | $25,608,000 | 4.17% |
| TPG GP A, LLC | 18,716,306 | $279,247,000 | 2.79% |
| Casdin Capital, LLC | 2,650,000 | $39,538,000 | 1.11% |
| Lombard Odier Asset Management (Switzerland) SA | 996,116 | $14,862,000 | 0.95% |
| Coastal Bridge Advisors, LLC | 301,929 | $4,505,000 | 0.94% |
| HARBOR CAPITAL ADVISORS, INC. | 119,547 | $1,784,000 | 0.65% |
| Pier Capital, LLC | 294,968 | $4,401,000 | 0.46% |
| Navalign, LLC | 64,428 | $961,000 | 0.38% |
| Gratus Capital, LLC | 191,871 | $2,863,000 | 0.26% |